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with cholestasis which was treated medically. In her early thirties, she
developedworsening jaundice andpruritus andunderwent biliary diver-
sionwith almost complete resolution of her symptoms. She subsequently
developed hematochezia due to cancerous rectal polyps requiring
abdominoperineal resection, colostomy, and take down of the biliary di-
version. As a result, she developed recurrent cholestasis complicated by
cirrhosis, portal hypertension, and malabsorption. Given the patient's
portal hypertension she was not a candidate for further abdominal sur-
geries as a source of therapeutic intervention of cholestasis and thus a
liver transplantation evaluation was initiated. Her cardiac and pulmo-Decisions with regard to transplant and organ allocation in patients
with multi-system organ dysfunction are signiﬁcantly complex. By
nature, genetic syndromes often involve congenital abnormalities in
multiple organ systems, Alagille syndrome being a prime example
with paucity of bile ducts resulting in cholestatic hepatic dysfunction
and cardiac and pulmonary vascular abnormalities. Transplantation of
the liver is indicated in 21–33% of patients; however, eligibility may
be hindered by congenital cardiopulmonary defects [1]. These congeni-
tal heart defects may impose adverse hemodynamic effects prior to,
during, and following transplantation. Clinical indications for liver
transplantation in patients with Alagille syndrome include chronic
liver disease, portal hypertension and impaired quality of life with
growth failure secondary to severe cholestasis, xanthomatosis, and re-
fractory pruritus. We report the case of a young woman with hepatic,
pulmonary vascular, and cardiac dysfunction as a result of Alagille syn-
drome and describe how a transcatheter therapeutic approach aided
clinical optimization of her cardiopulmonary system prior to liver
transplantation.
This 40-year-old woman with a diagnosis of Alagille syndrome with
signiﬁcant hepatic and cardiopulmonary involvement was referred for
an evaluation in a multidisciplinary transplant clinic. The patient waswer, Suite 1901a, Houston, TX
Smithson).
land Ltd. This is an open access articlinitially diagnosed with Alagille syndrome at age 3 when she presented
nary comorbidities, however, required further evaluation.
The patient had previously undergone surgical ligation of a patent
ductus arteriosus at 2 months of age, surgical closure of an atrial septal
defect at age 2 and a surgical pulmonary valvotomy at age 18. Upon ini-
tial clinical evaluation she reported recent progressively worsening
dyspnea on exertion, worsening exercise tolerance and intermittent
headaches. She denied chest pain, orthopnea, paroxysmal nocturnal
dyspnea, lower extremity edema or syncope. Physical examination
demonstrated a well-nourished, well-developed female with Alagille
facies in no apparent distress with a grade 2/6 systolic and diastolic
murmur at the left upper sternal border. 12-Lead ECG demonstrated
normal sinus rhythmwith ﬁrst-degree atrioventricular block and right-
ward axis. Transthoracic echocardiogram showed left ventricular func-
tion to be at the lower limits of normal with estimated ejection
fraction of 50–54%, a normal functioning right ventricle, bicuspid aortic
valve without signiﬁcant stenosis and right ventricular hypertension
with an estimated right ventricular systolic pressure of 60–65 mm Hg.
As a result, the patient underwent diagnostic coronary angiogram
and cardiac catheterization that demonstrated no evidence of signiﬁ-
cant coronary disease, but she had hemodynamics suggestive of severe
right and left main pulmonary artery stenosis (hemodynamics reported
in Table 1). Computed tomography angiography showed severe right
atrial and right ventricular enlargement with severe stenosis of the
right pulmonary artery trunk and moderate stenosis of the left pulmo-
nary artery trunk (Figs. 1–8). A bicuspid aortic valve was seen and the
aortic root was dilated at 4 cm. Cardiovascular magnetic resonance im-
aging demonstrated normal estimated right ventricular function with
estimated ejection fraction of 66%. There was evidence of mild right
ventricular enlargement and hypertrophy with estimated right ventric-
ular end diastolic volume of 166 ml and end systolic volume 51 ml.e under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Table 1
Hemodynamics.
Variable (mm Hg) Initial
evaluation
Prior to
intervention
Post
intervention
Right atrium 14/13 (11) 8/8 (7) 19/18 (17)
Right ventricle 80/12 63/7 50/12
Main pulmonary artery 73/11 (32) 50/12 (25)
Right pulmonary artery 40/12 (21) 29/11 (18) 50/13 (32)
Pulmonary capillary wedge (RPW) 15 12 23
Left pulmonary artery 46/13 (24) 43/2 (21) 45/16 (29)
Pulmonary capillary wedge (LPW) 16 10 23
Left ventricle 160/15 162/65 (101)
Aorta 161/58 (99) 132/62 (90)
Fig. 2. 3D reconstruction of pulmonary artery stenoses. SVC = superior vena cava, LA =
left atrium, RPA= right pulmonary artery, LPA = left pulmonary artery.
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of 50 ml and regurgitant fraction of 45%. In summary, although the
patient had signiﬁcant pulmonic regurgitation, the right ventricular
pressure overload as a result of bilateral main branch PA stenosis was
felt to be the main hemodynamic lesion.
Given the patient's symptomatology and hemodynamics, it was
deemed that the patient should undergo therapeutic intervention of
her pulmonary arterial disease prior to consideration for liver tranplant.
Since the patient had signiﬁcant liver pathology secondary to Alagille
syndrome and multiple prior cardiac surgeries, a catheter-based treat-
ment approach was planned rather than open surgical repair.
Prior to intervention the patient was intubated and initiated on me-
chanical ventilation supported by a fraction of inspired oxygen of 60%.
Complete hemodynamics under general anesthesia were acquired
prior to intervention (Table 1). Following hemodynamics and angiogra-
phy, wire access was obtained in both the right and left distal pulmo-
nary arteries, and then sequential stenting of the right main followed
by the left main pulmonary artery performed by placement of a Palmaz
XL P3110 stent (Johnson and Johnson, New Brunswick, NJ) deployed by
an 18 mm and 20 mm NuMED Balloon-in-Balloon (BIB) catheter
(NuMED, Hopkinton, New York), respectively. Kissing balloon post-
dilation was performed using an 18 mm and 20 mm Atlas balloon
(Bard Inc., Tempe, AZ) at high pressures. During deﬂation, however,
the right PA stent appeared to recoil, and therefore a second stent was
implanted within the ﬁrst to add radial strength (EV3 Mega-LD
36mm on 18mm BIB balloon Covidien, Mansﬁeld, MA). Final hemody-
namics demonstrated an elevation in ﬁlling pressures, but no residual
gradient from the RV to the distal PAs bilaterally (Table 1). The patient
was successfully extubated in the catheterization lab and transferred
in stable condition to the intensive care unit for post-procedureFig. 1. Coronary CT angiogram demonstrating bilateral pulmonary artery stenoses. RPA=
right pulmonary artery, LPA = left pulmonary artery, AA = ascending aorta, DA =
descending aorta, RMB= right main bronchus, LMB= left main bronchus.monitoring. She was subsequently discharged the day after her proce-
dure. On follow-up, she reported signiﬁcant improvement in her
symptoms.
Evaluation for liver transplantation in patients with Alagille
syndrome is a complex process because of the multitude of clinical
manifestations of the disease as well as its inherent multi-organ in-
volvement. Speciﬁcally, pulmonary artery stenosis with right ventricu-
lar pressure overload is a common issue in patients with Alagille
syndrome, and right ventricular hypertension may contribute to con-
gestive hepatopathy in the allograft post liver transplant in addition to
the inherentmorbidity of right heart failure. Congenital heart transcath-
eter intervention may be beneﬁcial in palliating and optimizing the he-
modynamics of these patients prior to transplant.
There have been conﬂicting reports on the effect of high right ven-
tricular pressures and severity of pulmonary stenosis on outcomes in
patients with Alagille Syndrome undergoing liver transplantation. In a
series by Tzakis et al. 23 patients with Alagille syndrome and cardiac
malformations underwent liver transplantation. Mean survival was
57% at 4.4 years, with three deaths attributed to cardiopulmonary dis-
ease [2]. This led to the conclusion that patients with cardiopulmonaryFig. 3. Cardiac MRI demonstrating pulmonic valve insufﬁciency. RA= right atrium, RV=
right ventricle, mPA=main pulmonary artery.
Fig. 4. Pulmonary angiogram prior to intervention demonstrating right pulmonary artery
stenosis. RPA = right pulmonary artery, LPA = left pulmonary artery, mPA = main
pulmonary artery.
Fig. 6. Fluoroscopy in the left anterior oblique projection demonstrating full expansion of
the right pulmonary artery stent and partial inﬂation of the left pulmonary artery stent
with the inner balloon only. RPAs= right pulmonary artery stent, LPAs= left pulmonary
artery stent.
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tation. In contrast, in a series reported by Png et al. that involved 16 chil-
dren, no correlation between severity of pulmonary artery stenosis and
hemodynamic changes during transplantationwas found [3]. Due to the
limited experience of patients with Alagille syndrome undergoing liver
transplantation and the heterogeneity of cardiac manifestations of the
disease onemust extrapolate the literaturewith caution and individual-
ize therapeutic options for patients with Alagille syndrome and cardiac
manifestations of the disease.
Congenital heart disease is the second most common manifestation
of Alagille syndrome affecting greater than 90% of patients. Most com-
monly, pulmonary outﬂow tract is involved with peripheral pulmonary
stenosis being the hallmark. In his review of 80 cases, Alagille et al. re-
ported an incidence of 70% of isolated peripheral pulmonary stenosis
[4]. Tetralogy of Fallot, ventricular septal defects, atrial septal defects,
and aortic stenosis also exist and are not uncommon (approximately
15% of cases). Other reported cardiovascular malformations include hy-
poplasia of the pulmonary vascular tree, pulmonary atresia, truncusFig. 5. Pulmonary angiogram prior to intervention demonstrating left pulmonary artery
stenosis. LPA = left pulmonary artery.arteriosus, and coarctation of the aorta. It is important to note that
heart disease is the most common cause of death in the infant, while
liver disease is themost common cause of death in the child and adoles-
cent patient. The twenty-year predicted life expectancy for patients
with Alagille syndrome is 75% [5].
Alagille syndrome is an autosomal dominant disorder that is caused
by defects in genes involved in the Notch signaling pathway, most fre-
quently due to a mutation in the JAG1 gene, but occasionally NOTCH2
or others. The prevalence is 1:70,000 [6]. Like most genetic disorders,
the phenotype is variable, but often includes ﬁve aspects (i.e. the ‘classic
criteria’): a paucity of bile ducts and resulting cholestasis, congenital
heart disease, dysmorphic facies, skeletal abnormalities, and eye pathol-
ogy. Paucity of bile ducts is the most common manifestation (approxi-
mately 95% affected), similar to, but distinct from, biliary atresia. The
spectrum of dysmorphic facies includes broad forehead, deep set eyes,
pointed chin, and upslanting palpebral ﬁssures. The characteristic skel-
etal abnormality is “butterﬂy vertebrae”, or failure of fusion of the ante-
rior vertebral arches. The typical eye ﬁnding of Alagille syndrome isFig. 7. CT chest demonstrating right pulmonary artery stent POST intervention. RPAs =
right pulmonary artery stent.
Fig. 8. CT chest demonstrating left pulmonary artery stent post intervention. LPAs = left
pulmonary artery stent.
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the normal population. Other features of Alagille syndrome include in-
tracranial hemorrhage, vascular anomalies, dysplastic kidneys, renal tu-
bular acidosis, failure to thrive, pancreatic insufﬁciency, and mental
retardation [7,8]. Following the diagnosis of Alagille syndrome,manage-
ment involves a multidisciplinary approach. A pediatrician, geneticist,
gastroenterologist, cardiologist and other specialists pertaining toman-
ifested pathology should be involved in routine care. Patients should
have comprehensive assessment of liver function, detailed cardiac as-
sessment, AP spinal X-ray, ophthalmic assessment, renal ultrasound
and renal function testing. Monitoring of growth, development, diet
and nutritional status should be emphasized and expert opinion should
be sought if needed.
While surgical intervention remains the most commonly employed
modality in the care of patients with complex congenital defects in
Alagille syndrome, most centers favor a catheter-based approach for in-
tervention in peripheral pulmonary arterial stenoses secondary to the
high rate of restenosis (up to 60%) with surgical intervention [9]. This
high rate of restenosis is seen primarilywith proximal pulmonary artery
lesionswhile distal lesions are oftennumerous and are difﬁcult to access
surgically. These factors favor a transcatheter interventional approach
to pulmonary artery stenoses. The goal for intervention on pulmonary
artery stenosis is to alleviate the elevation of right ventricular pressure
that will ultimately lead to clinical right-sided heart failure as well as
signiﬁcant hemodynamic sequelae when the patient becomes eligible
for liver transplantation.
Intravascular stenting to thepulmonary artery has been employed in
children since themid-1980s [10]. Pulmonary artery balloon angioplas-
ty and/or stenting, is one of themost common procedures performed in
cardiac catheterization laboratories treating congenital heart disease.
The success rate with low-pressure balloons varies in the literature
ranges from 34 to 71%.With high-pressure balloons the success rate ap-
proaches 56–72% [11]. For branchpulmonary artery stenosis, balloon di-
lation with intravascular stent placement yields a greater increase in
vessel diameter and greater reduction in pressure gradient than does
sole balloon dilation [12]. The double balloon technique, which employs
the use of two smaller balloons rather than one large balloon thereby
resulting in less trauma to the femoral veins, has been shown to besuccessful [13]. Cutting-balloon angioplasty has been shown to be effec-
tive when conventional balloon angioplasty fails [14]. In the cases of
pulmonary valve stenosis, percutaneous pulmonary valvuloplasty is
the preferred method of therapeutic intervention. Studies have shown
good long-termoutcomes [15]. Clinical experience involvingpulmonary
rehabilitation in Alagille syndrome is limited. To date, there are no re-
ports addressing the natural history of either elevated right ventricular
pressures or pulmonary arterial hypertension in Alagille syndrome or
the impact of surgical or catheter-based intervention on survival.
A recent multi-institutional registry demonstrated a 10% procedure-
related risk of high severity adverse events in patients undergoing pul-
monary artery rehabilitation. Presence of N2 indicators of hemodynamic
vulnerability, low weight, use of cutting balloons and operator experi-
ence of less than 10 years were signiﬁcant risk factors for high severity
related procedures [16].
This case highlights the utility of transcatheter intervention as a via-
ble method of therapeutic management in adult patients with Alagille
syndrome who may present with clinical signs of right heart failure
secondary to pulmonary artery stenosis. Given the complexity of
cardiac manifestations of Alagille syndrome, clinical and hemodynamic
optimization may be accomplished with catheter-based therapeutic
intervention and optimize hemodynamics in patients prior to liver
transplantation and may even preclude the need for concomitant
heart transplant consideration. Pulmonary arterial interventions should
be limited to specialized centers with congenital and pediatric
interventionalists with high volume labs.References
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